Related Experiment Videos
Simvastatin improves endothelial function in patents with subclinical hypothyroidism
Dursun Duman1, Sinan Sahin, Kenan Esertas
1Department of Cardiology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. drduman@excite.com
Heart and Vessels
|March 29, 2007
Summary
Simvastatin significantly improved endothelial function and lipid profiles in subclinical hypothyroidism patients. Levothyroxine (LT-4) showed no significant effect, suggesting simvastatin
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Pharmacology
Background:
- Subclinical hypothyroidism (SCH) is linked to impaired endothelial function, potentially due to dyslipidemia.
- Endothelial dysfunction is a precursor to cardiovascular events.
Purpose of the Study:
- To compare the effects of simvastatin and levothyroxine (LT-4) on lipid profiles and endothelial function in SCH patients.
- To investigate the impact of dyslipidemia treatment on endothelial function in SCH.
Main Methods:
- Randomized controlled trial with 59 newly diagnosed SCH patients.
- Three groups: no treatment, LT-4, or simvastatin.
- Assessment of endothelium-dependent vasodilation (EDV) and endothelium-independent vasodilation (EIV) at baseline and 8 months.
Main Results:
- Simvastatin significantly reduced total cholesterol, triglycerides, and LDL-cholesterol.
- Simvastatin treatment led to a significant increase in EDV (P < 0.01), correlating with LDL reduction.
- LT-4 therapy showed a non-significant trend towards increased EDV; EIV remained unchanged in all groups.
Conclusions:
- Simvastatin effectively improves brachial artery endothelial function and dyslipidemia in SCH patients.
- The hypolipidemic effect of simvastatin may contribute to improved endothelial function.
- LT-4 therapy did not demonstrate significant benefits for endothelial function in this cohort.
Related Concept Videos
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...